Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
91.35
-1.16 (-1.25%)
Products

FDA Accepts Application For Merck’s Keytruda (Pembrolizumab) As Adjuvant Therapy For Stage IB(≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection

Published: 06/13/2022 11:20 GMT
Merck & Co Inc (MRK) - FDA Accepts Application for Merck’s Keytruda® (pembrolizumab) As Adjuvant Therapy for Stage Ib (≥4 Centimeters)-iiia Non-small Cell Lung Cancer Following Complete Surgical Resection.
Merck & Co Inc - FDA Has Set a Prescription Drug User Fee Act (pdufa), Or Target Action, Date of January 29, 2023.